IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

# Integrating Artificial Intelligence In Stem Cell Therapy And Regenerative Medicine

Miss. Neha Govind Sidlambe[1], Miss. Mayur Balu Mokal[2], Dr. D.K. Vir[3], Miss. Manisha Prakash Sirsath[4], Miss. Divya Raju Madhikar.

1(student),2(Associate Professor[guide]),3(Principal),4(student),5(student).

Department of Pharmaceutical Science and Technology.

Shree Goraksha College of Pharmacy and Research Center, Chhatrapati Sambhaji Nagar, Maharashtra, India.

**Abstract:** The concept of healing in modern medicine is shifting toward regenerative approaches that restore health at the cellular level. Stem cell therapy plays a central role by replacing or repairing damaged cells and is being used for a wide range of autoimmune, inflammatory, neurological, orthopedic, and traumatic disorders, with potential applications in anti-aging and disease prevention. Challenges remain, including errors in cell identification and processing. To address these issues, medicine is increasingly using artificial intelligence to analyse, select, and predict the behaviour of productive stem cells. This review highlights how AI is improving the precision and safety of stem cell therapy, paving the way for more efficient regenerative treatments with minimal side effects.

**Keywords:**

Precision Medicine, Disease Prevention, Anti-Aging, Neurological Disorders, Predictive Analysis, Future of Healing.

**Introduction:**

Stem cells can self-renew and differentiate into specialized cells, helping maintain tissue balance and support repair. After injury, a stem cell divides into one stem cell and one progenitor cell, the latter being a committed intermediate that develops into specialized cells **[1]**. Stem cells are categorized by source as embryonic or adult stem cells **[2]**, and by potency as totipotent, pluripotent, multipotent, oligopotent, or unipotent **[3]**.

Stem cells are undifferentiated cells capable of self-renewal and differentiation into specialized cell types. Pluripotent stem cells, including embryonic stem cells (ESCs) from the blastocyst's inner cell mass, can form nearly all cell types but raise ethical concerns due to embryo destruction. The development of induced pluripotent stem cells (iPSCs) in 2007 provided an ethical alternative, as reprogrammed adult cells closely resemble ESCs and are useful for disease modeling, drug testing, and regenerative medicine **[4][5]**.

Stem cells play a crucial role in tissue repair, and growing evidence supports their therapeutic potential in regenerative medicine **[6]**. Stem cell therapies—using embryonic, induced pluripotent, or adult stem cells from patients or donors—show promise for treating cardiovascular, neurological, spinal, skin, and blood disorders, though challenges remain in delivery, quality control, ethics, and safety assessment **[3][6]**. Because these therapies generate complex data, artificial intelligence can assist significantly in their development. AI systems mimic human cognitive functions such as learning, pattern recognition, reasoning, and adaptation **[7]**, and recent machine learning and deep learning approaches have been applied to improve regenerative therapies **[8]**.

**Objective:**

**1. Enhance Precision and Accuracy**: To accurately identify, classify, and select healthy and viable stem cells for transplantation and regenerative treatments.

**2. Improve Cell Differentiation Prediction:** To predict and control how stem cells differentiate into specific cell types, ensuring targeted and effective therapy outcomes.

**3. Automate Data Analysis:** To handle and analyse large sets of biological and genetic data from stem cell research more efficiently than manual methods.

**4. Minimize Human Error:** To reduce errors in cell identification, culture, and application through AI-guided automation and image-based diagnostics.

**5. Personalize Treatment Plans:** To design patient-specific stem cell therapies using AI algorithms that analyse genetic, clinical, and molecular data.

**6. Optimize Manufacturing and Quality Control:** To monitor stem cell production processes in real time, ensuring consistent quality, purity, and potency of stem cells.

**7. Accelerate Research and Drug Discovery:** To speed up the discovery of new regenerative treatments by simulating biological processes and predicting therapeutic outcomes.

**8. Enhance Monitoring and Prognosis:** To track patient responses after stem cell therapy and predict long-term outcomes using AI-based predictive models.

**Stem cells: types and characteristics**

Stem cells can grow and differentiate into various cell types. They were once classified as embryonic or adult based on origin, but discoveries such as cellular reprogramming and the presence of somatic stem cells in fetal and neonatal tissues have led to a classification based on biological potential: pluripotent and multipotent stem cells **[9]**.

**Embryonic stem cells:** Embryonic stem cells come from a 4–5-day-old blastocyst containing an outer trophoblast and an inner cell mass, which forms the embryo. The zygote is totipotent, able to form both embryo and placenta **[2,9]**. The inner cell mass provides pluripotent stem cells, which can develop into almost all body cell types but not the placenta. As ESCs differentiate, they generate cells from the three germ layers—mesoderm, endoderm, and ectoderm. Unipotent stem cells, in contrast, can form only one specific cell type and have limited self-renewal, though they still have therapeutic potential **[10]**.

**Adult stem cell:** Adult (somatic) stem cells are found in tissues such as bone marrow, brain, liver, muscle, skin, retina, and the eye limbus. They include hematopoietic stem cells, which produce blood cells, and mesenchymal stem cells, which form bone, cartilage, and fat. They can be collected without harming an embryo, making them ethically acceptable. During development, pluripotent cells become multipotent germ-layer cells, which then form unipotent or progenitor cells involved in tissue repair **[2,9]**.




**Fig no.1: Pluripotent vs. Multipotent Stem cells -The Genesis**

**Induced Pluripotent Stem Cell:** Induced pluripotent stem cells (iPSCs), first generated by Takahashi and Yamanaka in 2006, were created by reprogramming mature fibroblasts using four transcription factors—OCT4, SOX2, KLF4, and MYC. This approach was soon applied to human cells, marking a major breakthrough in regenerative medicine. Building on earlier work in nuclear reprogramming and transcription factor discovery, iPSCs display ESC-like pluripotency, enabling differentiation into all three germ layers without the ethical concerns of embryo-derived cells. Their patient-specific origin also makes them valuable for disease modeling and personalized therapy. However, challenges such as low reprogramming efficiency, incomplete differentiation, genomic and epigenetic instability, and tumor risk still limit their clinical use **[11,7]**.




**Fig No.2: Synthesis of induced Pluripotent Stem Cell**

**Regenerative potential of stem cells**

Stem cells play a crucial role in tissue repair due to their ability to generate diverse human cell types **[6]**. They aid regeneration by differentiating into required cells, releasing paracrine factors that reduce inflammation and activate resident progenitor cells, and promoting angiogenesis to improve blood supply. They also protect tissues by limiting cell death, fibrosis, and excessive scarring while regulating immune responses **[12]**. Their regenerative capacity has shown promise in conditions such as congenital disorders, cardiovascular disease, neurodegeneration, and retinal damage. Despite this progress, major challenges persist, including handling complex biological data, selecting optimal cell types, understanding cell behavior, improving delivery methods, and overcoming the high cost and time demands of cell culture. Predicting therapeutic outcomes and mortality risks also remains difficult **[6]**.

### Stem cell therapy

Stem cell therapy involves the use of viable human stem cells—ESCs, iPSCs, or adult stem cells—in autologous or allogeneic forms to treat various diseases. Their differentiation potential enables the replacement or repair of damaged tissues and organs. However, successful clinical application requires identifying safe, stable, and accessible cell sources capable of multilineage differentiation, making careful selection of the appropriate stem cell type essential for therapeutic success **[3]**.

### Artificial intelligence (AI)

The term "Artificial Intelligence" was introduced by John McCarthy at the 1956 Dartmouth Conference, defining it as the creation of machines capable of simulating human thought. With technological advancement, AI has grown into a major scientific field focused on systems that can learn, reason, and make decisions with minimal human input **[13]**. Applications such as optical character recognition (OCR) show how AI transforms unstructured data into usable information for improved decision-making. Broadly, AI replicates human cognitive abilities—learning, problem-solving, and prediction—while processing far larger datasets **[7]**. In healthcare, AI complements human expertise by enabling data analysis, pattern recognition, and real-time clinical decision support. Machine learning (ML) and deep learning (DL) are the most widely used AI techniques in this sector **[5]**.




**Fig No.3: Commonly Used Machine Learning and Deep Learning Algorithms**

### Machine learning (ML)

Machine Learning (ML) enables computer systems to learn from data and improve performance without explicit programming. By identifying patterns, ML supports prediction and classification tasks **[5]**. It includes four main approaches: supervised, unsupervised, semisupervised, and reinforcement learning.

• Supervised learning uses labeled data for regression or classification.

• Unsupervised learning finds hidden structures through methods like clustering.

• Semisupervised learning combines limited labeled data with abundant unlabeled data, useful in areas such as medical imaging.

• Reinforcement learning teaches models through rewards to optimize long-term outcomes, though it is still emerging in medicine **[14]**.

Common supervised algorithms include ANNs, SVMs, naïve Bayes, random forests, k-NN, decision trees, and AdaBoost **[5]**.

**Deep learning (DL)**

Deep Learning (DL) is an advanced form of ML that learns from large datasets using multilayered neural networks capable of processing complex inputs such as images, speech, and text. Built on artificial neural networks, DL models function as universal approximators and handle high-dimensional data efficiently **[6]**. DL has significantly improved tasks like computer vision, speech recognition, and natural language understanding, and plays a key role in robotics by enhancing perception, object detection, and autonomous decision-making in dynamic environments **[15]**. Unlike traditional ML, which relies on manual feature engineering, DL automatically extracts features through multiple hierarchical layers. Its rapid growth is driven by advancements in computing power and hardware accessibility **[6]**.

**Table no.1: Key differences in artificial intelligence, machine learning and deep learning [6]**

| FEATURE | AI | ML | DL |
|---|---|---|---|
| **Definition** | Integrates human-like intelligence into machines using rules, logic, and algorithms. | Enables systems to learn from previous data and improve performance without explicit programming. | Uses deep neural network architectures to learn complex patterns directly from data. |
| **Subset relationship** | Broad field that includes both ML and DL. | Subset of AI focused on data-driven learning. | Subset of ML that utilizes multi-layer neural networks. |
| **Functionality** | Performs reasoning, decision-making, and problem-solving tasks. | Uses algorithms to analyse data, recognize patterns, and generate predictions. | Processes information through layered neural networks to extract deep, hierarchical features. |
| **Learning approach** | Utilizes rule-based, knowledge-based, or data-driven strategies. | Learns from data using supervised, unsupervised, or reinforcement methods. | Employs hierarchical neural layers that convert simple features into abstract representations. |
| **Human intervention** | Depends on human-designed rules and logic. | Requires human involvement for data labeling and model training. | Needs minimal human input due to automated representation learning. |
| **Data dependency** | Can operate on smaller datasets or predefined rules. | Requires moderately sized structured datasets for effective learning. | Relies on very large labeled datasets for training deep networks. |
| | | | |
| **Processing power** | Utilizes complex reasoning processes and computational logic. | Employs mathematical algorithms requiring moderate computational resources. | Demands high computational power due to intensive deep neural network operations. |
| **Efficiency** | Efficiency is linked to the performance of embedded ML and DL systems. | More efficient than traditional AI but less capable than DL when handling large datasets. | Highly efficient on large-scale data because of automatic feature extraction. |
| **Applications** | Applied in areas like natural language processing, robotics, and vision systems. | Used in recommendation engines, forecasting, and data pattern analysis. | Suited for image classification, speech recognition, and autonomous technologies. |

**Convolutional Neural Network (CNN)**

Convolutional Neural Networks (CNNs) are specialized neural networks designed for image-based tasks such as classification, detection, and pattern recognition. Inspired by the visual cortex, CNNs have evolved from early models like the Neocognitron (1980) and LeNet (1998) to modern deep architectures following the breakthrough of AlexNet in 2012, which led to advanced models such as VGGNet, GoogleNet, ZFNet, and ResNet.

CNNs extract hierarchical features through stacked convolution and pooling layers—early layers detect simple edges, while deeper layers capture complex shapes. Filters learn patterns by sliding over image patches, preserving spatial structure and generating feature maps. After multiple layers, the extracted features are flattened and passed to fully connected layers for final classification. This multilayer feature-learning process underlies their effectiveness in image analysis **[16,14]**.

**Artificial Neural Networks (ANN)**

Artificial Neural Networks (ANNs) are computational models inspired by the brain, made up of interconnected neurons that learn by adjusting connection weights. Early networks were simple, but the development of multi-layer architectures enabled them to solve more complex tasks. Shallow networks with one hidden layer work for simple problems, whereas deep networks with multiple hidden layers capture more abstract features and handle large datasets effectively **[17]**.

Each neuron processes numerical inputs using an activation function, and information flows through layers until an output is produced. Deep neural networks improve through iterative learning, making them widely used in prediction, adaptive control, and pattern recognition, even when relationships in the data are not obvious **[6]**.

**Natural Language Processing (NLP)**

Natural Language Processing (NLP) is a branch of AI that enables computers to understand and generate human language in forms like speech and text. It supports tasks such as translation, summarization, sentiment analysis, question answering, and speech recognition. NLP must handle challenges including ambiguity, context dependence, idioms, and domain-specific vocabulary. Techniques such as syntactic and semantic analysis, part-of-speech tagging, and named entity recognition are commonly used.

As models grow larger, performance improves but requires more data, computation, and energy. Current research focuses on developing efficient NLP methods suitable for resource-limited environments while improving multilingual support and reducing bias **[7]**.




**Fig No.4: Representation of commonly used ML algorithms in artificial intelligence**

## An Overview of Artificial Intelligence in Healthcare

Artificial intelligence has long supported both virtual and physical aspects of healthcare. In the virtual domain, tools such as deep-learning systems analyse electronic health records to assist clinicians in diagnosis and treatment planning. In the physical domain, robotics supports elderly care, enhances surgical precision, and enables targeted nanorobot-based drug delivery. These advancements trace back to early robotic concepts by Leonardo DaVinci, which evolved into today's sophisticated robotic-assisted systems used in complex urological and gynecological procedures **[13]**.

## Role of Artificial Intelligence in Stem Cell Therapies

Traditional stem-cell and regenerative-medicine workflows face challenges including complex data, manual colony assessment, and variable decision-making. For iPSCs, manual evaluation of morphology and quality is slow and error-prone, limiting scalability. AI helps overcome these issues by enabling automated colony segmentation, quality assessment, pattern recognition, and predictive modelling. Through machine learning and deep learning, AI enhances data mining, differentiation analysis, and outcome prediction, improving accuracy and efficiency in stem cell research **[18]**. AI-driven systems—

including ML and ANNs—support automated cell processing, culture optimization, selection of patient-specific cell types, and image-based analysis for tissue engineering and drug discovery **[6]**.

### Current Trends in Stem Cell Therapy by AI

### Embryonic Stem Cells (ESCs)

AI and deep-learning models are used to assess ESC pluripotency and differentiation status. Studies using large image datasets with architectures like ResNet, DenseNet, and Triplet-CNN have achieved accuracies above 94–97%. Automated segmentation tools in MATLAB, C++, and Java assist in nucleus detection, ESC counting, and feature extraction from microscopy images, improving efficiency in ESC evaluation **[18]**.

### induced Pluripotent Stem Cells (iPSCs)

Genomic instability and developmental immaturity are major challenges in iPSC research. AI supports non-invasive monitoring, differentiation assessment, and detection of subtle morphological changes without the need for staining. Integration with robotics enables automated culture, high-throughput screening, and remote monitoring. AI-driven platforms help simulate pluripotency, build organoids, model diseases, and accelerate drug discovery, including early detection of toxicity and prediction of treatment responses **[8]**.

### Hematopoietic Stem Cells (HSCs)

Hematopoietic stem cells (HSCs) are widely used for treating malignant, non-malignant, and autoimmune diseases. Their success depends on donor–recipient compatibility, though complications such as GvHD, infections, and haemorrhagic cystitis remain concerns. Despite newer treatment options reducing transplant demand, HSCs continue to play a key therapeutic role **[5]**.

### Mesenchymal Stem Cells (MSCs)

Because MSCs vary by source and exhibit senescence, treatment outcomes are inconsistent. AI combined with immunofluorescence imaging enables precise detection of aging markers, improving quality control. These AI-driven phenotyping tools support large-scale production of high-quality MSCs. Given their accessibility, multipotency, and immunomodulatory capacity, MSCs remain valuable for biomedical and dental applications, with AI helping optimize their therapeutic performance **[10,20]**.

### Stem Cell Therapy in the Treatment of Diseases

### Stem Cell Therapy in Diabetes

Diabetes is a major global disease, with 537 million adults affected in 2021 and 8.4 million living with type 1 diabetes. MSCs from bone marrow, adipose tissue, and umbilical sources support islet transplantation by reducing inflammation, improving graft survival, and promoting angiogenesis. AI enhances MSC-based diabetes therapies by enabling personalized predictions and optimizing regenerative strategies **[21]**.

### Stem Cell Therapy in Cancer

Cancer is the second leading cause of death worldwide and is influenced by genetic, lifestyle, and environmental factors. Stem-cell-based therapies aim to regenerate damaged tissues and support immune responses. Recent trials using genetically engineered autologous MSCs for gastrointestinal tumors show promise. AI further improves stem-cell-based cancer treatment by selecting optimal cells, analyzing behavior, and predicting therapeutic responses, supporting more targeted and personalized approaches **[22]**.

### Stem Cell Therapy in Heart Failure

Heart failure often results from long-term cardiomyopathy. Early studies showed that bone-marrow stem cells can promote angiogenesis and tissue repair after ischemic injury through factors like VEGF and HGF. MSCs are particularly promising due to their accessibility and strong paracrine effects. A key challenge is tracking transplanted cells in the heart, requiring reliable markers for localization and monitoring of fate after delivery **[23,24]**.

**Stem Cell Therapy in Anti-Aging Treatment**

Skin aging results from intrinsic factors (genetics, hormones) and extrinsic influences (UV radiation, pollution). Conventional therapies provide limited deep repair. Stem-cell-derived exosomes—especially from adipose-derived MSCs—offer deeper regeneration by delivering growth factors and miRNAs, reducing inflammation, and stimulating tissue repair. Their ease of collection and strong regenerative capacity make AMSC-derived exosomes promising next-generation anti-aging treatments **[25]**.

**Stem Cell Therapy in Neurological Diseases**

Neurological disorders involve progressive loss of neural tissue driven by protein aggregation and neuronal degeneration **[26]**. Stem-cell-derived neural cells offer new possibilities for treating diseases such as Parkinson's, Alzheimer's, ALS, and MS. Modern trials aim not only to slow disease progression but also to restore lost function, marking a major step forward in regenerative neurology **[3]**.

| Disease | Stem Cell Types Studied | Preclinical Findings | Clinical Trial Finding | Challenges & limitations |
|---|---|---|---|---|
| **Alzheimer's Disease (AD)** | MSCs, NSCs, iPSC-derived neurons | Reduce amyloid-β burden, decrease inflammation, enhance neurogenesis and synaptic repair, partial cognitive improvement in animals | Early-phase MSC trials show safety; slight cognitive stabilization but no strong disease modification | Poor graft survival, limited integration into brain circuits, difficulty targeting affected regions, need for long-term follow-up |
| **Parkinson's Disease (PD)** | ESC/iPSC-derived dopaminergic neurons, MSCs, NSCs | Replenish dopaminergic neurons, improve motor symptoms, restore dopamine release, reduce inflammation | Early ESC/iPSC trials show safety and early motor improvement; fatal tissue grafts gave mixed results | Risk of dyskinesias, immune reaction, standardizing dopaminergic cell production, ensuring long-term functional integration |
| **Multiple sclerosis (MS)** | NSCs, OPCs, MSCs, hematopoietic stem cells | Promote remyelination, stabilize axons, reduce inflammation, enhance regulatory T-cell activity | aHSCT can induce long-term remission in aggressive MS; MSCs safe with mild improvements | Targeted delivery to demyelinated regions, uncertainty in remyelination capacity, risk in aHSCT, variable patient responses |
| **Stroke** | MSCs, NSCs, iPSC-derived neural cells | Reduce infarct size, limit inflammation, enhance angiogenesis, support neurogenesis; functional recovery in animal models | MSC trials safe but inconsistent clinical benefits (MASTERS, TREASURE) | Low cell survival in ischemic tissue, variable patient timing, poor engraftment, limited migration to lesion |
| **Amyotrophic Lateral Sclerosis (ALS)** | NSCs, MSCs, motor neuron progenitors | Protect motor neurons, reduce inflammation, improve survival modestly in animal models | Early trials safe; intrathecal or intraspinal MSC/NSC delivery shows no clear functional improvement | Harsh inflammatory microenvironment, limited neuron replacement, safety concerns for repeated dosing |

| | | | | |
|---|---|---|---|---|
| **Huntington's Disease (HD)** | NSCs, MSCs, iPSC-derived neurons, fetal striatal cells | Improve motor function, reduce inflammation, support neuronal survival; partial restoration of striatal circuits | Limited trials; fetal grafts feasible but develop HD-like pathology over time | Risk of mutant HTT transfer to graft, graft degeneration, need for gene-corrected cells, small trial sizes |
| **Spinal Cord Injury (SCI)** | NSCs, NPCs, MSCs, ESC-derived OPCs | Promote neuronal repair, reduce inflammation, support axonal regrowth, improve locomotor recovery in animals | MSC trials show safety with mild functional gains; OPC trials ongoing | Scar formation, inhibitory microenvironment, limited long-distance axonal growth, long-term survival unclears |

**Stem Cell Therapy in Autoimmune Diseases**

Autoimmune diseases arise when the immune system mistakenly attacks the body's own tissues, affecting organs such as the skin, joints, glands, and internal organs. Examples include rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes.

AI supports earlier diagnosis and better monitoring by analysing large datasets and predicting disease progression using machine learning and deep learning models. Stem cell therapy offers additional benefits: HSCs help reset the immune system by replacing dysfunctional immune cells, while MSCs provide strong anti-inflammatory and tissue-repair effects. Clinical findings show that autologous HSC transplantation improves neurological outcomes in multiple sclerosis, and MSC therapy reduces disease severity in systemic lupus erythematosus, improving kidney function **[27]**.

**Stem Cell Therapy in Orthopedic Disorders**

Orthopedic conditions—including osteoarthritis, fractures, cartilage injuries, and bone tumors—significantly affect mobility and quality of life worldwide. Regenerative orthopedics uses biological therapies such as cell-based treatments, purified cytokines, and PRP to enhance tissue repair **[29]**. Stem-cell-based therapies using MSCs, chondrocytes, engineered immune cells, and iPSCs aim to regenerate damaged cartilage and bone but also present specific challenges **[28]**.

AI-driven robotic systems are improving orthopedic diagnosis and surgery by enhancing precision and ~~reducing human error. These tools support planning and treatment prediction for complex bone and joint~~ disorders **[29]**.

**Broadening the Scope of AI in Various Disorders**

AI-enhanced stem cell therapies are showing promise across multiple medical fields:

**Orthopedic disorders:** AI improves stem cell selection and differentiation for conditions like osteoarthritis, avascular necrosis, bone non-union, and cartilage damage.

**Neurological disorders:** In MS, spinal cord injury, ALS, and stroke, AI helps design personalized stem cell treatment plans.

**Ophthalmologic disorders:** AI supports stem-cell-based approaches for retinal degeneration, corneal defects, and age-related macular degeneration.

**Cardiac disorders:** For myocardial infarction and cardiomyopathy, AI guides optimal cell selection and improves heart regeneration.

**Microvascular/surgical disorders:** AI optimizes stem cell use for wound healing and limb ischemia by enhancing blood vessel formation.

**Pediatric disorders:** AI-personalized therapies are explored for cerebral palsy, autism, osteogenesis imperfecta, BPD, HIE, muscular dystrophy, and SMA.

**Respiratory disorders:** In ARDS, AI predicts responses to stem cell therapy and helps determine optimal dosing.

**Dermatologic disorders:** AI customizes stem cell–based skin rejuvenation and repair.

**Endocrinologic disorders:** In diabetes, AI assists in regenerating insulin-producing cells through guided stem cell strategies.

**Gastroenterologic/hepatologic disorders:** AI tailors stem cell therapies for liver cirrhosis by analysing damage patterns [30].

## Summary

AI is transforming stem cell research by improving accuracy, scalability, and clinical performance. Technologies such as ML, DL, CNNs, ANNs, and NLP enable automated cell identification, pluripotency assessment, colony evaluation, and prediction of differentiation outcomes. These advancements support high-throughput screening, organoid development, disease modelling, and drug discovery.

Across ESCs, iPSCs, MSCs, and HSCs, AI enhances cell characterization, detects abnormalities early, and improves treatment planning. Clinically, AI-supported stem cell therapies are advancing care in diabetes, cancer, cardiac diseases, neurological and autoimmune disorders, orthopedic injuries, and aging-related degeneration.

## Future Perspective:

AI is expected to greatly enhance stem cell therapy by supporting automated cell manufacturing, real-time monitoring, and early detection of genetic instability. Deep learning models will refine differentiation predictions and accelerate disease modelling, organoid generation, and drug discovery. In clinical settings, AI will integrate imaging, genomic, and physiological data to personalize regenerative treatments while predicting risks such as graft failure or tumor formation.

## Conclusion

AI is strengthening stem cell therapy by improving precision, safety, and therapeutic outcomes. It addresses major challenges in cell characterization, manufacturing, quality control, and outcome prediction. With its growing role across multiple diseases—including diabetes, cancer, neurological conditions, autoimmune disorders, orthopedic injuries, and aging—AI is helping make regenerative medicine more effective and patient-specific.

Together, AI and stem cell science are paving the way for the next generation of precision regenerative therapies.

## References:


1.Roopa R Nadig, Stem cell therapy – Hype or hope? A review, J Conserv Dent | Oct-Dec 2009 | Vol 12 | Issue 4 131.

2.Bagher Larijani, Ensieh Nasli Esfahani, Stem Cell Therapy in Treatment of Different Diseases, Acta Medica Iranica, 2012; 50(2): 79-96.

3.Riham Mohamed Aly, Current state of stem cell-based therapies: an overview, Stem Cell Investig 2020;7:8.

4.Minjae Kim, Integrating Artificial Intelligence to Biomedical Science: New Applications for Innovative Stem Cell Research and Drug Development, Technologies 2024, 12, 95.

5.Sayali Mukherjee, Recent trends in stem cell-based therapies and applications of artificial intelligence in regenerative medicine, World J Stem Cells 2021 June 26; 13(6): 521-541.

6.Mahmood S Choudhery, Applications of artificial intelligence in stem cell therapy, World J Stem Cells 2025 August 26; 17(8): 106086.

7.Mohamed Khalee, Artificial Intelligence in Computer Science, International Journal of Electrical Engineering and Sustainability (IJEES), Volume 2 | Number 2 | April-June 2024 | Pages 01-21.

8.Quan Duy Vo, The use of artificial intelligence in induced pluripotent stem cell-based technology over 10-year period: A systematic scoping review, journal pone, May 21, 2024.

9.Jesse K. Biehl, B.S., Introduction to Stem Cell Therapy, J Cardiovasc Nurs. 2009; 24(2): 98–105.

10.Nassim Rajabzadeh, Stem cell-based regenerative medicine, Stem Cell Investig 2019;6:18.

11.Shinya Yamanaka, Induced Pluripotent Stem Cells: Past, Present, and Future, j. stem.2012.05.005.

12.Irving L. Weissman, Stem Cells: Units of Development, Units of Regeneration, and Units in Evolution, Cell, Vol. 100, 157–168, January 7, 2000.

13.Mirra Srinivasan, Exploring the Current Trends of Artificial Intelligence in Stem Cell Therapy: A Systematic Review, Cureus 13(12): e20083. DOI 10.

14.Rene Y. Choi1, Introduction to Machine Learning, Neural Networks, and Deep Learning, Trans Vis Sci Tech.2020;9(2):14.

15.Mohsen Soori, Artificial intelligence, machine learning and deep learning in advanced robotics, a review, Cognitive Robotics 3 (2023) 54–70.

16.Ramanaesh Rao Ramakrishna, Stem cell imaging through convolutional neural networks: current issues and future directions in artificial intelligence technology, Ramakrishna et al. (2020), PeerJ, DOI 10.7717/peerj.10346.

17.Wahab Khan, Exploring the frontiers of deep learning and natural language processing: A comprehensive overview of key challenges and emerging trends, Natural Language Processing Journal 4 (2023) 100026.

18.Priyanshi Goya, Developments in Stem Cell Therapy by Utilizing Artificial Intelligence, Current Pharmaceutical Design, XXXX, Vol. XX, No. XX.

19.Elena RUSU, Current status of stem cell therapy: opportunities and limitations, Turkish Journal of Biology, Volume 40 Number 5.

20.Elham Saberian, Applications of artificial intelligence in regenerative dentistry: promoting stem cell therapy and the scaffold development, fcell.2024.1497457.

21.Lisha Mou, Advancing diabetes treatment:the role of mesenchymal stem cells in islet transplantation, Front. Immunol, 2024, 15:1389134.

22.Sahar Sak, AI-Driven Approaches to Stem Cell Therapy in Cancer: Innovations and Challenges, International Journal of BioMed Insights 2(1) 24-37, 2025.

23.Mohammed A. Chowdhury, Stem cell therapy for heart failure in the clinics: new perspectives in the era of precision medicine and artificial intelligence,Front. Physiol 2024,14:1344885.

24.Bodo E. Straue, Stem Cell Therapy in Perspective, Circulation. 2003;107:929-934.

25.Yan-Xiu Jin, The Anti-Aging Effects of Adipose-Derived Mesenchymal Stem Cell Exosomes on Skin and Their Potential for Personalized Skincare Applications, Clinical, Cosmetic and Investigational Dermatology 2025:18 2267–2284.

26.Ramyar Rahimi Darehbagh, Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives, European Journal of Medical Research (2024) 29:386.

27.Mohd Afza, Advancements in the treatment of autoimmune diseases: Integrating artificial intelligence for personalized medicine, Trends in Immunotherapy 2024, 8(2), 8970.

28.Jing Wang, Advances in cell therapy for orthopedic diseases: bridging immune modulation and regeneration, Front. Immunol 2025 16:1567640.

29.Madhan Jeyaraman, Leveraging Artificial Intelligence and Machine Learning in Regenerative Orthopedics: A Paradigm Shift in Patient Care, Cureus 2023 15(11): e49756. DOI 10.7759.

30.Vinay Suresh, Advancements of artificial intelligence-driven approaches in the use of stem cell therapy in diseases or disorders: clinical applications and ethical issues, Evi. 2024:2(3):1-DOI:10.61505/evidence.2024.2.3.88.